Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50

Benzinga Newsdesk www.benzinga.com Neutral 58.4%

Neg 0% Neu 58.4% Pos 0%

Jefferies analyst Akash Tewari initiates coverage on Latigo Biotherapeutics (NASDAQ:LTGO) with a Buy rating and announces Price Target of $50.